Intravitreales Bevacizumab bei der neovaskulären altersabhängigen Makuladegeneration

Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25: 111–118

Adamis AP, Shima DT, Tolentino MJ et al. (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114: 66–71

Avery RL, Pieramici DJ, Rabena MD et al. (2006) Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration. Ophthalmology 113: 363

Charbel Issa P, Scholl HP, Holz FG, Knolle P, Kurts C (2005) Das Komplementsystem und dessen mögliche Beteiligung an der Pathogenese der altersabhängigen Makuladegeneration (AMD). Ophthalmologe 102: 1036–1042

Ferrara N (1995) Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab Invest 72: 615–618

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186

Gragoudas ES, Adamis AP, Cunningham ET et al. (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805–2816

Holz FG, Pauleikhoff D, Klein R, Bird AC (2004) Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol 137: 504–510

Holz FG, Pauleikhoff D, Spaide RF, Bird AC (2004) Age-related macular degeneration. Springer, Berlin Heidelberg New York Tokio

Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342

Jaissle GB, Szurman P, Bartz-Schmidt KU (2005) Empfehlung für die Durchführung von intravitrealen Injektionen – Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft (DOG) und des Berufsverbands der Augenärzte Deutschland (BVA). Klin Monatsbl Augenheilkd 222: 390–395

Krzystolik MG, Afshari MA, Adamis AP et al. (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120: 338–346

Michels S, Rosenfeld PJ (2005) [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis]. Klin Monatsbl Augenheilkd 222: 480–484

Mordenti J, Cuthbertson RA, Ferrara N et al. (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27: 536–544

Pharmacological Therapy for Macular Degeneration Study Group (1997) Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 115: 865–872

Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36: 331–335

Scholl HP, Weber BH, Nothen MM et al. (2005) Y402H-Polymorphismus im Komplementfaktor H und altersabhängige Makuladegeneration (AMD). Ophthalmologe 102: 1029–1035

Spilsbury K, Garrett KL, Shen WY et al. (2000) Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 157: 135–144